

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
	APPLICANT Banerjee, Partha S.	
	FILING DATE June 22, 2001	GROUP 1617

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
MB	A	0	0	2	4	6	4	1	09/27/01	Yang	424	46	04/02/01
	B	0	0	3	2	1	4	9	03/14/02	Kensey	514	1	04/24/01
	C	0	0	6	1	8	3	5	05/23/02	Kensey	514	1	04/09/01
	D	0	0	8	1	2	6	6	06/27/02	Woolfe <i>et al.</i>	424	46	08/14/01
	E	0	0	9	9	0	1	3	07/25/02	Piccarriello <i>et al.</i>	514	12	08/22/01
	F	0	1	0	3	2	6	0	08/01/02	Clarke <i>et al.</i>	514	630	08/15/01
	G	0	1	5	1	5	9	7	10/17/02	Banerjee <i>et al.</i>	514	629	07/22/01
	H	4	3	3	5	1	2	1	06/15/82	Phillipps <i>et al.</i>	424	241	02/13/81
	I	4	9	9	2	4	7	4	02/12/91	Skidmore <i>et al.</i>	514	653	08/23/89
	J	5	1	2	6	3	7	5	06/30/92	Skidmore <i>et al.</i>	514	651	11/29/90
	K	5	2	2	5	4	4	5	07/06/93	Skidmore <i>et al.</i>	514	651	02/19/92
	L	5	2	7	0	3	0	5	12/14/93	Palmer	514	171	09/03/91
	M	5	2	9	0	8	1	5	03/01/94	Johnson <i>et al.</i>	514	651	11/25/91
	N	5	8	7	4	0	6	3	02/23/99	Briggner <i>et al.</i>	424	45	02/26/96
	O	5	9	8	0	9	4	9	11/09/99	Trofast	424	489	01/09/98
	P	5	9	8	3	9	5	6	11/16/99	Trofast	141	1	01/09/98
	Q	6	0	3	0	6	0	4	02/29/00	Trofast	424	46	01/09/98
	R	6	2	8	7	5	4	0	09/11/01	Trofast	424	46	11/02/99
MB	S	6	3	6	9	1	1	5	04/09/02	Ward	514	728	03/20/00

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
MB	T	0	0	0	6	1	2	1	02/10/00	PCT				X*
	U	0	0	0	7	5	6	7	02/17/00	PCT				X*
hvs	V	0	0	1	6	8	1	4	03/30/00	PCT				

EXAMINER

DATE CONSIDERED

05/15/00

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1014SERIAL NO.  
09/887,496LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee, Partha S.FILING DATE  
June 22, 2001GROUP  
1617

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUB CLASS	Translation	
														Yes	No
18		W	0	0	2	8	9	7	9	05/25/00	PCT				X*
		X	0	0	3	0	6	1	2	06/02/00	PCT				
		Y	0	0	3	0	6	1	3	06/02/00	PCT				
		Z	0	0	3	3	8	9	2	06/15/00	PCT				
		AA	0	0	4	7	2	0	0	08/17/00	PCT				
		AB	0	0	4	8	5	8	7	08/24/00	PCT				
		AC	0	0	5	1	5	9	1	08/08/00	PCT				
		AD	0	0	5	3	1	8	7	09/14/00	PCT				
		AE	0	0	5	3	1	8	8	09/14/00	PCT				
		AF	0	1	2	7	1	0	7	04/19/01	PCT				
		AG	0	1	2	2	9	5	6	04/05/01	PCT				X*
		AH	0	1	3	2	1	6	3	05/10/01	PCT				
		AI	0	1	3	9	7	4	5	06/07/01	PCT				
		AJ	0	1	5	4	6	6	4	08/02/01	PCT				
		AK	0	1	7	0	1	9	8	09/27/01	PCT				
		AL	0	1	7	8	7	3	5	10/25/01	PCT				
		AM	0	1	7	8	7	4	5	10/25/01	PCT				
		AN	0	1	8	3	5	1	7	11/08/01	PCT				
		AO	0	1	8	5	1	3	7	11/15/01	PCT				
		AP	0	1	8	9	4	9	1	11/29/01	PCT				
		AQ	0	2	0	3	9	5	8	01/17/02	PCT				
		AR	0	2	0	7	6	7	2	01/31/02	PCT				
		AS	0	2	1	1	8	0	3	02/14/02	PCT				
		AT	0	2	2	8	3	6	8	04/11/02	PCT				
W		AU	0	2	3	0	3	9	4	04/18/02	PCT				

EXAMINER

DATE CONSIDERED

05/14/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
18025-1014SERIAL NO.  
09/887,496LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
Banerjee, Partha S.FILING DATE  
June 22, 2001GROUP  
1617

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
M	AV	0	2	3	4	2	3	7	05/02/02	PCT				
	AW	0	2	3	8	1	0	7	05/16/02	PCT				
	AX	0	2	4	3	8	0	6	06/06/02	PCT				
	AY	0	2	4	5	6	8	2	06/13/02	PCT				
	AZ	0	2	4	9	6	1	6	06/27/02	PCT				
	BA	02	0	5	1	4	8	3	07/04/02	PCT				
	BB	02	0	6	0	5	3	2	08/08/02	PCT				X*
	BC	02	0	6	0	5	3	3	08/08/02	PCT				X*
	BD	02	0	6	0	8	7	5	08/08/02	PCT				
	BE	02	0	6	0	8	9	6	08/08/02	PCT				
	BF	02	0	6	0	8	9	8	08/08/02	PCT				
	BG	02	0	6	2	3	1	7	08/15/02	PCT				
	BH	02	0	8	3	1	1	3	10/24/02	PCT				
	BI	1	1	5	7	6	8	9	11/28/01	EP (A1)				
	BJ	1	2	2	9	0	3	4	08/07/02	EP (A1)				
	BK	1	2	3	6	4	6	7	09/04/02	PCT				
	BL	19	5	4	1	6	8	9	05/15/96	DE				X*
	BM	19	8	3	5	3	4	6	02/10/00	DE				X*
	BN	9	3	1	1	7	7	3	06/24/93	PCT				
	BO	9	5	0	5	8	0	5	03/02/95	PCT				
	BP	9	6	1	8	3	8	4	06/20/96	PCT				
	BQ	9	6	1	9	1	9	8	06/27/96	PCT				
	BR	9	6	1	9	9	6	8	07/04/96	PCT				
	BS	9	6	3	2	0	9	5	10/17/96	PCT				
M	BT	9	8	0	5	3	0	2	02/12/98	PCT				

EXAMINER

DATE CONSIDERED

6/5/14/09

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
	APPLICANT Banerjee, Partha S.	
	FILING DATE June 22, 2001	GROUP 1617

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
MB	BU	9	8	1	5	2	8	0	04/16/98	PCT				
	BV	9	8	3	1	3	5	1	07/23/98	PCT				
	BW	9	8	3	1	3	5	2	07/23/98	PCT				
	BX	9	8	3	4	5	9	5	08/13/98	PCT				X*
	BY	9	8	3	4	5	9	6	08/13/98	PCT				
	BZ	9	8	4	1	1	9	3	09/24/98	PCT				
	CA	9	9	0	0	1	3	4	01/07/99	PCT				
	CB	9	9	1	5	1	8	2	04/01/99	PCT				
	CC	9	9	3	0	7	0	3	06/24/99	PCT				
	CD	9	9	4	0	9	3	9	08/19/99	PCT				
	CE	9	9	4	8	4	7	6	09/30/99	PCT				
MB	CF	9	9	6	1	0	0	3	12/02/99	PCT				

X\* = English Language Derwent Abstract is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MB	CG	Barnes, P.J., "Scientific rationale for inhaled combination therapy with long-acting $\beta_2$ -agonists and corticosteroids," <i>Eur. Respir. J.</i> <u>19</u> : 182-191 (2002)
	CH	Campestrini <i>et al.</i> , "Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection," <i>Journal of Chromatography B</i> <u>704</u> : 221-229 (1997)
	CI	Cazzola <i>et al.</i> , "Long-Acting $\beta_2$ -Agonists in the Treatment of Acute Exacerbations of COPD," <i>Clin. Drug Invest.</i> <u>22(6)</u> : 369-376 (2002)
	CJ	Derwent#010743444, WPI Acc No.:1996-240399/199625 for German Patent Application DE 19541689, "Medicament contg. ciclesonid and beta2-sympathomimetic - for treating chronic obstructive respiratory disease,"
MB	CK	Derwent#012030009, WPI Acc No.:1998-446919-199838 for PCT Patent Application WO 98/34595, "Pressurised liquid aerosol propellant for pharmaceutical inhalers - contains carbon dioxide and hydro-fluoroalkane; gives more consistent dosing and a better particle size spectrum,"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
	APPLICANT Banerjee, Partha S.	
	FILING DATE June 22, 2001	GROUP 1617

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	CL	Derwent#013011051, WPI Acc No.:2000-182903/200016 for PCT Patent Application WO 00/06121, "Aerosol propellant comprising dinitrogen monoxide and hydrofluoroalkane and optionally containing a pharmaceutically active substance,"
	CM	Derwent#013023586, WPI Acc No. 2000-195437/200017, for PCT Patent Application WO 00/07567 "Aerosol formulation for drug administration, containing small amount of cromoglycate or nedocromil salt as drug carrier, to improve dispersion stability and accuracy of dosing,"
	CN	Derwent#013024375, WPI Acc No.: 2000-196226/200018 for German Patent Application DE 19835346, "Two-part drug capsule for use in powder inhalers is formed from hydrophobic plastics, preferably high density polyethylene,"
	CO	Derwent#013227765, WPI Acc No. 2000-399639/200034, for PCT Patent Application, WO 00/28979 "Use of magnesium stearate for stabilization of dry powder inhalation formulations to improve resistance to moisture,"
	CP	Derwent#013790372, WPI Acc No.: 2001-274583/200129, for PCT Patent Application, WO 01/22956 "Drug combination of soft steroid and beta-2-adrenoceptor agonist, administered by inhalation for effective treatment of respiratory or allergic diseases, e.g. asthma,"
	CQ	Derwent#014808338, WPI Acc No.:2002-629044/200268, for PCT Patent Application, WO 02/060533 "Medicament containing a betamimetic and an oxitropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	CR	Derwent#014816787, WPI. Acc No.: 2002-637493/200269, for PCT Patent Application, WO 02/060532 "Medicament containing a betamimetic and an ipratropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	CS	Eickelberg <i>et al.</i> , "Ligand-independent Activation of the Glucocorticoid Receptor by $\beta_2$ -Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and vascular Smooth Muscle Cells," <i>The Journal of Biological Chemistry</i> <u>274</u> (2): 1005-1010 (1999)
	CT	Farmer <i>et al.</i> , "6-Adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the I $\kappa$ B/NF- $\kappa$ B pathway," <i>Am. J. Physiol. Lung. Cell. Mol. Physiol.</i> <u>279</u> : 1675-682 (2000)
	CU	Greening <i>et al.</i> , "Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid," <i>The Lancet</i> <u>344</u> : 219-224 (1994)
MD	CV	Grootendorst <i>et al.</i> , "Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma," <i>Eur. Respir. J.</i> <u>17</u> : 374-379 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
	APPLICANT Banerjee, Partha S.	
	FILING DATE June 22, 2001	GROUP 1617

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Mg	CW	Ida, Hisashi, "Pharmacology of Formoterol, ( $\alpha$ RS)-3-formamido-4-hydroxy- $\alpha$ -[[( $\alpha$ RS)- $p$ -methoxy- $\alpha$ -methylphenethyl] amino] methyl] benzylalcohol fumarate dihydrate (BD 40A)," <i>Oyo Yakuri</i> <u>21(2)</u> : 201-210 (1981)
	CX	Ito <i>et al.</i> , "Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-16-Induced Histone H4 Acetylation on Lysines 8 and 12," <i>Molecular and Cellular Biology</i> <u>20(18)</u> : 6892-6903 (2000)
	CY	Ito <i>et al.</i> , "p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids," <i>The Journal of Biological Chemistry</i> <u>276(32)</u> : 30208-30215 (2001)
	CZ	Korn <i>et al.</i> , "Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells," <i>Eur. Respir. J.</i> <u>17</u> : 1070-1077 (2001)
	DA	Lipworth <i>et al.</i> , "Effects of Treatment with Formoterol on Bronchoprotection against Methacholine," <i>Am. J. Med.</i> <u>104</u> : 431-438 (1998)
	DB	Malolepszy <i>et al.</i> , "Safety of formoterol Turbuhaler™ at cumulative dose of 90 $\mu$ g in patients with acute bronchial obstruction," <i>Eur. Respir. J.</i> <u>18</u> : 928-934 (2001)
	DC	O'Connor, B.J., "Combination Therapy," <i>Pulmonary Pharmacology &amp; Therapeutics</i> <u>11</u> : 397-399 (1998)
	DD	Oddera <i>et al.</i> , "Salmeterol Enhances the Inhibitory Activity of Dexamethasone on Allergen-Induced Blood Mononuclear Cell Activation," <i>Respiration</i> <u>65</u> : 199-204 (1998)
	DE	Package Insert for: ADVAIR™ DISKUS <a href="http://fb.a-files.net/PackageInsert/Advair.htm">http://fb.a-files.net/PackageInsert/Advair.htm</a> (accessed on 09/26/02) (Copyright, 1999 Glaxo Wellcome Inc.)
	DF	Palmqvist <i>et al.</i> , "Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers," <i>Pulmonary Pharmacology &amp; Therapeutics</i> <u>14</u> : 29-34 (2001)
	DG	Pang, L. and A.J. Knox, "Regulation of TNF- $\alpha$ -induced eotaxin release from cultured human airway smooth muscle cells by $\beta_2$ -agonists and corticosteroids," <i>FASEB J.</i> <u>15</u> : 261-269 (2001)
	DH	Pang, L. and A.J. Knox, "Synergistic Inhibition by $\beta_2$ -Agonists and Corticosteroids on Tumor Necrosis Factor- $\alpha$ -Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells," <i>Am. J. Respir. Cell Mol. Biol.</i> <u>23</u> : 79-85 (2000)
	DI	Pauwels <i>et al.</i> , "Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma," <i>The New England Journal of Medicine</i> <u>337(20)</u> : 1405-1411 (1997)
Mg	DJ	Schreurs <i>et al.</i> , "A dose-response study with formoterol Turbuhaler™ as maintenance therapy in asthmatic patients," <i>Eur. Respir. J.</i> <u>9</u> : 1679-1683 (1996)

EXAMINER

DATE CONSIDERED

05/13/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
	APPLICANT Banerjee, Partha S.	
	FILING DATE June 22, 2001	GROUP 1617

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ML	DK	Seldon <i>et al.</i> , "Albuterol Does Not Antagonize the Inhibitory Effect of Dexamethasone on Monocyte Cytokine Release," <i>Am. J. Respir. Crit. Care Med.</i> <u>157</u> : 803-809 (1998)
	DL	Silvestri <i>et al.</i> , "Fluticasone and salmeterol downregulate <i>in vitro</i> , fibroblast proliferation and ICAM-1 or H-CAM expression," <i>Eur. Respir. J.</i> <u>18</u> : 139-145 (2001)
	DM	Sköld <i>et al.</i> , "Glucocorticoids Augment Fibroblast-Mediated Contraction of Collagen Gels by Inhibition of Endogenous PGE Production," <i>Proceedings of the Association of American Physicians</i> <u>111(3)</u> : 249-258 (1999)
	DN	Stewart <i>et al.</i> , "Acute formoterol administration has no argogenic effect in nonasthmatic athletes," <i>Medicine &amp; Science In Sports &amp; Exercise</i> <u>34(2)</u> : 213-217 (2002)
	DO	Vianna, E.O. and R.J. Martin, "Bronchodilators and Corticosteroids in the Treatment of Asthma," <i>Drugs of Today</i> <u>34(3)</u> : 203-223 (1998)
	DP	Wilding <i>et al.</i> , "Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study," <i>British Medical Journal</i> <u>314</u> : 1441-1446 (1997)
ML	DQ	Woolcock <i>et al.</i> , "Comparison of Addition of Salmeterol to Inhaled Steroids with Doubling of the Dose of Inhaled Steroids," <i>Am.J. Respir. Crit. Care Med.</i> <u>153</u> : 1481-1488 (1996)

EXAMINER

DATE CONSIDERED

05/14/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.